Hematology and Oncology Studies

PPD’s dedicated hematology and oncology team designs the optimal path for a drug's development. PPD optimizes timelines with accurate feasibility assessments and access to patients around the world as well as offers clients detailed knowledge of local and global clinical trial environments. Backed by our operational and therapeutic experts worldwide, we ensure trials stay on track at any stage of development, from preclinical through post-approval.

PPD conducted or supported 505 protocols in hematologic and oncologic indications involving almost 77,500 patients and approximately 15,900 sites between January 2004 and July 2009.

Established and Experienced Hematology and Oncology Team

Our dedicated hematology and oncology team, led by senior scientists and clinicians, consists of more than 500 professionals across the globe. Our senior medical director of hematology/oncology is board certified in internal medicine, hematology and medical oncology. With more than a decade of drug discovery and development experience in the pharmaceutical and biotech industry, he provides critical scientific oversight and leadership.

In addition, our international oncology advisory board provides clinical insight and drug development consulting for PPD clients.

Global Hematology and Oncology Investigator Network

PPD has a global network of more than 4,800 investigators with experience in hematology and oncology clinical research. We maintain close relationships and consulting agreements with physicians at most of the major tertiary and academic cancer treatment centers.

Hematology and Oncology Therapeutic Services

PPD provides development-focused therapeutic specialists from preclinical investigation through post-approval reporting, including:

• Investigator-initiated research protocols in oncology conducted in large cancer centers and local community practices, including IND exempt and non-exempt trials:
• • Non-small cell lung cancer
  • Prostate cancer
  • Breast cancer
  • Ovarian cancer
• Therapeutic safety profiles focused on specific cellular targets, enhancing the likelihood of accelerated access to the market
   
• Post-approval capabilities, including:
• • Late-stage trials
  • Consumer health
  • Online marketing and education
  • Medical communications